Novartis made a milestone payment related to clinical trial application (CTA/IND) and projected initiation of a Phase 1 trial.
MorphoSys chief scientific officer Dr. Marlies Sproll said the milestone is the first up to five clinical milestones expected from collaborators during the course of the year.
"In total, our collaboration with Novartis has resulted in seven clinical programs to date, three currently being in Phase 1 and four in Phase 2," Sproll added.